Press Releases

Nanotherapeutics’ GelVac™ Nasal Dry-Powder H5N1 Influenza Vaccine Shown to Be Safe in Early Stage Clinical Trial

• PRWeb - October 2011
  

Nanotherapeutics, Inc. announced the successful completion of a Phase 1 clinical trial of GelVac™ Nasal Dry-Powder H5N1 Influenza Vaccine. The trial assessed the safety of the novel intranasal dry-powder formulation vaccine for the H5N1 flu strain. more>

Nanotherapeutics Awarded BARDA Oral Radiation Drug Contract

• HHS Newsroom - September 2011
  

Nanotherapeutics receives $4.8 million BARDA contract to develop and improve the formulation and manufacturing processes of Diethylenetriaminepentaacetate (DTPA), a drug to treat internal contamination from radiation after a radiological attack. more>

Nanotherapeutics Acquires Two Cancer Treatment Agents in Late Stage Development for Relapsed AML and Cervical and Vaginal Cancers

• PRWeb Wire - July 2011
  

Nanotherapeutics acquired two cancer treatment drugs that are in late stage development. Cloretazine®, formerly known as Onrigen™ for the treatment of relapsed acute AML and Triapine® for solid tumors such as cervical and vaginal cancers. more>

Nanotherapeutics Gets FDA Orphan-Drug Status for NanoDTPA™ Capsules to Treat Radiation Exposure

• PRWeb Wire - June 2011
  

FDA approves orphan-drug designation to Nanotherapeutics' new oral capsule under development for treatment of radiation exposure. NanoDTPA™ capsule is one of several products the company is developing for chemical, biological, radiological and nuclear (CBRN) medical countermeasures. more>

Nanotherapeutics Receives U.S. Department of Defense Contract for Clinical Trial to Treat Dehisced Wounds with NanoDOX® Hydrogel

• Business Wire - November 2010
  

Nanotherapeutics, Inc. announced that it has been awarded a contract by the U.S.Department of Defense (DOD) to support a clinical trial for treating dehisced surgical wounds with the Company's NanoDOX® Hydrogel, a topical doxycycline hydrogel for chronic wounds. Nanotherapeutics is collaborating with Walter Reed Army Medical Center... more>

Nanotherapeutics Submits Investigational New Drug Application to FDA for Clinical Testing of Oral Drug to Treat Radiation Exposure

• Business Wire - August 2010
  

Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique... more>

Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease

• Business Wire - December 2009
  

Nanotherapeutics announced that it has acquired two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 from EPIX Pharmaceuticals, Inc. Ramoplanin is an oral antibiotic for the treatment of Clostridium difficile-associated disease (CDAD). PRX-3140 is an orally-bioavailable Alzheimer's treatment. more>

Soligenix Executes Option Agreement with University of Colorado on Thermostable Vaccine Technology

• PRNewswire - November 2009
  

Soligenix, Inc. received a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), and has formed a consortium to develop thermostable vaccine technology. Soligenix will partner with academic institutions, including Nanotherapeutics... more>

Nanotherapeutics Acquires Assets of DelSite

• Business Wire - October 2009
  

Nanotherapeutics, Inc., announced that it had acquired certain assets from DelSite (formerly Carrington Laboratories, Inc.) out of Chapter 7 bankruptcy proceedings in the U.S. Bankruptcy Court for the Northern District of Texas, Dallas Division. The DelSite assets acquired include the patented... more>

Nanotherapeutics Awarded $30.9 Million NIAID Contract to Develop Inhaled Antiviral for Prophylaxis and Treatment of Smallpox

• Business Wire - August 2009
  

Nanotherapeutics, Inc., has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major). more>

Nanotherapeutics Announces NanoBUP™ Capsule for Treating Opiate Addiction Demonstrated Bioavailability and Safety in Phase Ia Clinical Trial

• Business Wire - August 2009
  

NanoBUP™ Oral Buprenorphine / Naloxone Capsule, for treating opiate addiction, demonstrated strong oral absorption in a Phase Ia clinical trial. The 2 x 2mg capsule achieved significant oral bioavailability of 60 to 70 percent, in comparison to sublingual administration of buprenorphine/naloxone at a similar dose, as reported in published scientific reports. more>

BioFlorida Elects 12 New Directors to Its Board

• Business Wire - April 2009
  

BioFlorida, Florida's statewide trade association for the bioscience industry, has added Nanotherapeutics' Jim Talton among 12 new directors to its Board of Directors. The unanimous vote took place on March 30, 2009 at the Annual Member Meeting. more>

Nanotherapeutics Advances Two Clinical Programs

• Business Wire - March 2009
  

Nanotherapeutics, Inc. has submitted an Investigational New Drug (IND) application to the FDA for a Phase I clinical studies to assess the safety and pharmacokinetics of NanoBUP™ buprenorphine/naloxone capsule for the treatment of opiate addiction. NanoBUP™ is a stable, oral swallowed capsule containing buprenorphine/naloxone developed with the company’s proprietary NanoDRY^® particle delivery system. This new product is an immediate release capsule that allows buprenorphine to be absorbed more efficiently from the upper gastrointestinal tract upon ingestion, offering a less invasive route of administration and potentially reducing patient-to-patient variability.more>

Nanotherapeutics Files Investigational New Drug Application for NanoDOX™ Hydrogel to Treat Lower Extremity Diabetic Ulcers

• Business Wire - September 2008
  

Nanotherapeutics has submitted its first Investigational New Drug (IND) application to the FDA for a phase IIa clinical study for its product NanoDOX™ Hydrogel, a topical doxycycline hydrogel for chronic wounds. The randomized double-blind study will assess the safety and efficacy of the product on the healing rates of non-infected diabetic ulcers of the lower extremity. Assuming FDA approval, the Company expects to complete enrollment in early 2009.more>

Nanotherapeutics Announces Election of New Directors and Officers

• Business Wire - January 2008
  

Weaver H. Gaines, Director and Chairman of the Board
James R. Butler, Robert J. Hennessey, and James M. Matthew, Directors
Dennis S. Kristof, Treasurer
Bärbel Eppler, Ph.D., Secretary
James F. Kirk, Ph.D., Vice President R&D

Nanotherapeutics' Board of Directors elected Weaver H. Gaines as the company’s new non-Executive Chairman. Mr. Gaines is a serial entrepreneur, with 35 years of executive, legal, and entrepreneurial experience, particularly in early stage companies. He is also a trustee of Torrey Pines Institute of Molecular Studies and a director of the Florida Research Consortium. In other actions, the Board increased the number... more>

Nanotherapeutics Awarded $20 Million NIAID/BARDA Contract to Develop Inhaled Gentamicin for Treatment of Aerosol Exposure to Bioterrorism Agents

• Business Wire - October 2007
  

Nanotherapeutics has been awarded a $20 Million 4-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA) to develop an inhaled version of the injectable drug, gentamicin, a broad-spectrum antibiotic that is used as a first-line therapy for pneumonic plague and tularemia, Category A bioterrorism agents. Both diseases are highly infectious and could pose a serious danger if used as an aerosolized biological weapon. Using its novel particle formulation, the company has developed NanoGENT™, an inhaled dry-powder formulation of gentamicin, to provide early treatment for exposure to biological warfare agents, as well as TB and other respiratory infections.more>

HHS Awards Contracts for Advanced Development of New Medical Countermeasures

• Department of Health and Human Services (HHS) - October 2007
  

The Department of Health and Human Services (HHS) announced today the award of contracts totaling $55.3 million to four companies for the advanced development of anthrax antitoxins, therapeutics and antibiotics for use against plague and tularemia. The new Biological Advanced Research and Development Authority (BARDA) and NIH s National Institute for Allergy and Infectious Diseases (NIAID), provided funding for the new contracts. Through an agreement with BARDA, NIAID will manage the contracts.more>

Nanotherapeutics and the Vaccine Branch of the National Cancer Institute enter into Cooperative Research and Development Agreement (CRADA)

• Yahoo Finance! / www.nanotherapeutics.com - August 2007
  

Nanotherapeutics, Inc. has entered into a two year Cooperative Research and Development Agreement (CRADA) with the Vaccine Branch of the National Cancer Institute (NCI) to produce HIV peptide oral vaccine nanoparticles using the company's proprietary technology. The collaboration with NCI will employ the company's nanoparticle delivery system, which enables oral targeted delivery of macromolecules such as peptides, to facilitate oral delivery in the GI tract to improve immune response.more>

Nanotherapeutics, Inc. Named Most Promising Nanotechnology Industry Startup

• www.asme.org (American Society of Mechanical Engineers) - October 2006
  

Nanotherapeutics, Inc., a specialty pharmaceutical company based in Alachua, Fla., was cited as the most promising nanotechnology industry startup company in a recent competition conducted by ASME. Nanotherapeutics was one of six finalists in the 2006 NanoVenture Competition, held Sept. 21 in Honolulu. The competition ran in conjunction with the ASME Multifunctional Nano-composites International Conference.more>

RFM To Participate in Nanotherapeutics' Potential $2.4 Million SBIR Contract for Improvised Explosive Device Detection

• Yahoo! Finance - February 2006
  

RF Monolithics, Inc. today announced that its Wireless Systems Group is participating in a Small Business Innovation Research (SBIR) contract awarded to Nanotherapeutics, Inc. to develop an improved system to detect improvised explosive devices (IEDs).more>

Nanotherapeutics, Inc. Appoints Mento A. "Chuck" Soponis Chairman and CEO

• www.businesswire.com - January 2006
  

Nanotherapeutics, Inc., a privately held corporation focused on the development and application of proprietary drug delivery systems, announced today the appointment of Mento A. "Chuck" Soponis as Chairman and CEO to lead the company into its next phase of growth. Company also announces: New U.S. Patent Issued, $5.6 Million in Funding from the U.S. Navy and...more>

NIAID Awards $47 Million in New Effort to Develop Medical Countermeasures Against Radiological and Nuclear Threats

• National Institute of Health News - October 2005
  

The National Institute of Allergy and Infectious Diseases (NIAID) has issued more than $47 million for grants, contracts and interagency agreements as part of a new National Institutes of Health (NIH) research program on Medical Countermeasures Against Radiological and Nuclear Threats.more>

NIAID Awards First $27 Million Using New Bioshield Authorities

• National Institute of Health News - May 2005
  

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new...more>